AKT1 and breast carcinoma: Studies have confirmed that mTOR inhibitor (everolimus) combined with trastuzumab reversed trastuzumab resistance via the hyperactivated PI3K-AKT-MTOR pathway due to PTEN deficiency in patients with HER2-positive advanced breast cancer [33].